EpiBiologics Doses First Patient in EPI-326 Phase 1 Study
SAN MATEO, Calif., April 19, 2026 EpiBiologics has announced that the first patient has been dosed in its global...
Bispecific Antibody
Advertisement
Boehringer Advances Novel Combo Therapy in SCLC Trial
INGELHEIM, Germany, April 9, 2026 Boehringer Ingelheim has announced a strategic clinical trial collaboration with BioNTech to evaluate a...
Phanes Advances Spevatamig to Expansion in BTC Trial
SAN DIEGO, April 7, 2026 Phanes Therapeutics, Inc. has announced the initiation of the dose expansion phase in its...
Fortitude Advances T-Cell Therapy for Axial Disease
WALTHAM, Massachusetts, United States, April 7, 2026 Fortitude Biomedicines, Inc. announced progress on its lead immunology program, a first-in-class...
Akeso Cadonilimab Combo Delivers Strong NSCLC Trial Results
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
Advertisements
Adagene & Incyte Drive New MSS CRC Immunotherapy Study
San Diego, USA & Suzhou, China, April 2, 2026 Breakthrough Collaboration in Immuno-Oncology In a significant step forward for...
Gilead to Acquire Ouro for $2.1B Autoimmune Pipeline Boost
FOSTER CITY, CALIFORNIA, March 24, 2026 Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a...
Mestag Therapeutics Secures $40M for Clinical Trial
CAMBRIDGE, UK, March 17, 2026 Mestag Therapeutics has announced a $40 million financing round to advance its first-in-class oncology...
J&J Pasritamig Combo Shows Strong mCRPC Activity
RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...
Zenocutuzumab Extends Benefit in NRG1+ NSCLC
LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...
Advertisement
